Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 808 results for "hcv"

Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR[12] Rates in Genotype 1 Japanese Patients
PharmaVOICE

Enanta reports positive results from phase 3 CERTAIN-1 study o...

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company, announced results from AbbVie's phase 3 CERTAIN-1 study of 8 weeks of treatment with AbbVie's investigational, pan-genotypic, ribavirin (RBV)-free regimen of ... PharmaBiz, 1 week ago
[x]  

325 images for hcv

Before It's News, 23 hours ago
Before It's News, 2 days ago
HCPLive, 2 days ago
Before It's News, 3 days ago
Before It's News, 3 days ago
Before It's News, 4 days ago
HCPLive, 4 days ago
Before It's News, 4 days ago
Before It's News, 5 days ago
FOXBusiness.com, 3 hours ago
Autocar Professional

India Commercial Vehicle sales remain under pressure in December

Like the passenger vehicle industry, the critical medium and heavy commercial vehicle (M&HCV) segment in India is feeling the pressure of slowing sales. For most of 2016, the light commercial vehicle (LCV) segment remained largely positive ...
 Autocar Professional3 weeks ago Impact of demonetisation on Indian CV industry  MotorIndia6 days ago Is the commercial vehicle industry ready for BS IV?  Autocar Professional2 weeks ago Cash crunch slows down commercial vehicle sales  Rediff.com1 month ago

In the long-term,we are going to be a significant truck player

Mahindra & Mahindra Ltd (M&M), having invested over Rs 2000 crore in its Heavy Commercial Vehicles (HCV) business, is eyeing to be a significant players in the trucking industry. Currently, with a market share of 3.4 per cent built in a span of 6 years, ...
 The Hindu1 month ago 'In the long-term,we are going to be a significant truck player'  The Hindu1 month ago

MAN Trucks India unveils CLA EVO Range of HCV

MAN Trucks India Pvt. Ltd., a 100 percent subsidiary of MAN Truck and Bus AG, Germany, the world's leading manufacturer of trucks and buses, today unveiled the CLA EVO range of heavy commercial vehicles.The CLA EVO 25.300 6x4 BS4 Construction Tipper ...
 Business Standard1 month ago

Ashok Leyland bets big in LCV, ICV segments

After holding a significant position in the heavy and medium commercial vehicle (HCV) segments, Hinduja Group flagship Ashok Leyland pegs to ramp up its presence in the light and intermediate commercial vehicle segments with the launch of two new ...
 IChainnel3 days ago
India Infoline

Pre-buying ahead of BS IV remains key demand driver in the current quarter

The M&HCV (Truck) segment is likely to register 7-8% during the last quarter of FY 2017, as the impact demonetisation is offset by pick-up on account of pre-buying related to BS IV implementation, Subrata Ray said.
 India Infoline5 days ago

Ashok Leyland total sales at 10,731 units, down 12%

Ashok Leyland has experienced 9% decline in its sales of medium and heavy commercial vehicle (M&HCV) to 8,782 units in December 2016 as compared to 9,703 units in December 2015.
 India Infoline3 weeks ago ASHOK LEYLAND : total sales at 10,731 units, down 12%  4 Traders3 weeks ago Ashok Leyland sees upward growth curve of 28% with total sales of 12,533 units  India Infoline2 months ago Ashok Leyland's December sales down by 12% at 10,731 units  Smart Investor3 weeks ago
[x]  
Nasdaq

EMA to review Gilead's marketing application for HCV med SOF/VEL/VOX

The European Medicines Agency (EMA) accepts for review Gilead Sciences' (NASDAQ: GILD ) Marketing Authorization Application (MAA) seeking approval of its once-daily single-table regimen of sofosbuvir 400 mg, velpatasvir 100 mg and voxilaprevir 100 ...
 Seeking Alpha3 days ago EMA validates Validates Gilead's MAA for chronic hepatitis C therapy  Pharmaceutical Business Review6 hours ago Gilead Release: EMA Validates Company???s Marketing Authorization Application For Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)  BioSpace2 days ago Gilead's MAA For Investigational Chronic Hepatitis C Therapy Validated By EMA  Nasdaq3 days ago
[x]  
Cancer Therapy Advisor

Sorafenib Survival Effect in Liver Cancer May Depend on HCV-Status

Reuters Health Information By Will Boggs MD | January09,2017 NEW YORK (Reuters Health) - Treatment with sorafenib is associated with improved overall survival in hepatitis C virus (HCV)-positive patients with hepatocellular cancer (HCC), ...
 General Medicine eJournal1 week ago Sorafenib Effect on HCC Survival Depends on Hepatitis Status  Doctors Lounge2 weeks ago Sorafenib survival benefit in HCC depends on etiology  PM 3602 weeks ago Effect of Sorafenib on OS Dependent on Viral Status  Cancer Therapy Advisor2 weeks ago
Yahoo! Finance

Pennsylvania To Provide HCV Treatment To Mumia Abu-Jamal; A Boon For Gilead?

Click to enlarge Mumia Abu-Jamal. Source: New York Times States are constitutionally obligated to provide medically necessary healthcare to incarcerated people. Now a federal judge has ordered Pennsylvania Department of Corrections ("DOC") to ...
 Seeking Alpha2 weeks ago FEDERAL JUDGE ORDERS STATE PROVIDE MUMIA ABU-JAMAL WITH HCV TREATMENT BY GILEAD SCIENCES, INC. (NASDAQ : Gild)  4 Traders2 weeks ago State Ordered to Treat Former Black Panther Mumia Abu-Jamal for Hepatitis C  Real Health2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less